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Abstract: Nonalcoholic fatty liver disease (NAFLD) usually takes decades to develop into cirrhosis, which limits the 
longitudinal study of NAFLD. This work aims at developing a NAFLD-caused cirrhosis model in gerbil and examining 
the dynamic relationship between hepatic lipid metabolism and cirrhosis. We fed gerbil a high-fat and high-cho-
lesterol diet (HFHCD) for 24 weeks, and recorded the gerbil’s phenotype at 3, 6, 9, 12, 15, 18, 21, 24 weeks. The 
model’s pathological process, lipid metabolism, oxidative stress, liver collagen deposition and presence of relevant 
cytokines were tested and evaluated during the full-time frame of disease onset. The gerbil model can induce non-
alcoholic steatohepatitis (NASH) within 9 weeks, and can develop cirrhosis after 21 weeks induction. The model’s 
lipids metabolism disorder is accompanied with the liver damage development. During the NAFLD progression, 
triglycerides (TG) and free fatty acids (FFA) have presented distinct rise and fall tendency, and the turning points 
are at the fibrosis stage. Besides that, the ratios of total cholesterol (CHO) to high-density lipoprotein cholesterol 
(HDL-C) exhibited constant growth tendency, and have a good linear relationship with hepatic stellate cells (HSC) 
(R2 = 0.802, P < 0.001). The gerbil NAFLD cirrhosis model has been developed and possesses positive correlation 
between lipids metabolism and cirrhosis. The compelling rise and fall tendency of TG and FFA indicated that the 
fibrosis progression can lead to impairment in lipoprotein synthesis and engender decreased TG level. CHO/HDL-C 
ratios can imply the fibrosis progress and be used as a blood indicator for disease prediction and prevention.
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Introduction
Cirrhosis is a severe stage of liver dysfunction 
and is most commonly caused by alcohol, viral 
hepatitis, and NAFLD. Since NAFLD has become 
a leading health problem worldwide, especially 
for those people who are living with obesity [1], 
the lack of a suitable animal model for NAFLD-
caused cirrhosis has aroused more and more 
attention. It has been suggested that 20% of 
the adult population in the world now has 
NAFLD [2], with an increase of 90% morbidity in 
obese populations [3]. The whole natural histo-
ry of NAFLD has four stages: simple steatosis, 
NASH, fibrosis and cirrhosis. Fibrosis can lead 
to an increased morbidity rate from cirrhosis, 
hepatic failure, metabolic syndrome associated 
cardiovascular and cerebrovascular diseases, 
and hepatic carcinoma [4]. The clinical pro- 
gression from simple steatosis to cirrhosis of 
NAFLD usually takes decades, strongly impact-
ing the NAFLD-caused cirrhosis mechanism 
research and related drug development. For 
this reason, finding a suitable animal model 
for NAFLD-caused cirrhosis study becomes 
crucial.
Currently, NAFLD animal models can be divid- 
ed into two types, one is the genetic model, 
and the other one is a drug and/or diet-induced 
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model. Most commonly used genetic models 
are related to lipid metabolism genes, such as 
ob/ob mouse, db/db mouse, (fa/fa) Zucker 
rats, PPARα-/- mouse, and PNPLA3 transgenic 
mouse. Whereas, spontaneous mutations are 
very rare in the clinic, and normally those cases 
are based on multiple gene mutations, which 
causes differences between clinic and the 
genetic models. For those drug and/or diet-
induced models, the typical diets used to in- 
duce NAFLD are methionine choline deficient 
(MCD) diet [5, 6], high-fat diet (HFD, including 
high-fat and high-fat, high-cholesterol diets), 
and high-carbohydrate diet (HCD) [7]. Com- 
pared with the diet of human the MCD diet is 
abnormal, but HFD and HCD are similar. 
Additionally, comparing with the other animal 
models, our literature searches show that the 
rat HFD model is the more widely used model 
to investigate the etiology and pathogenesis 
of NAFLD [8-10]. However, this type of model 
cannot induce cirrhosis [11, 12]. The induced 
animal can reach NASH stage and fibrosis 
stage, but the fibrosis is mild and unstable. So 
in the past decade, a great emphasis has be- 
en placed on the animal models for NAFLD 
study.
The Mongolian gerbil (Merionesunguiculatus) is 
a fat-sensitive animal [13-18]. Its plasma lipid 
response to dietary fatty acids is more sensi-
tive than humans, even without dietary cho- 
lesterol [13-18]. Due to its reported lipemic 
responses to dietary fat and cholesterol [13-
20], the gerbil has been chosen to establish 
NAFLD animal model. Moreover, previous re- 
search findings have pointed out that NASH is 
associated with metabolic syndrome [21-25], 
and gerbil has the tendency to acquire diabe- 
tes spontaneously [26]. We attempt to estab-
lish a stable animal model, which shares the 
major clinical pathogenic factors: HFD, male, 
and lipid metabolism disorder [2]. Since we 
have clearly observed fibrosis stage and veri-
fied the stability of a gerbil NASH model in our 
former work [27, 28], the gerbil NASH model 
was used for developing a NAFLD-caused cir-
rhosis model and studying the mechanism. This 
is the first study to undertake a longitudinal 
observation of the whole natural history of 
NAFLD in gerbil and to investigate the dynamic 
relationship between hepatic lipid metabolism 
and cirrhosis. This is also the first comprehen-
sive description of the new established NAFLD-
caused cirrhosis model. The model’s patho- 
logical process, lipid metabolism, oxidative str- 
ess, liver collagen deposition and related cyto-




A total of 72 male littermate Mongolian ger- 
bils (Merionesunguiculatus) were obtained fr- 
om Zhejiang Academy of Medical Sciences, 
Zhejiang Center of Laboratory Animals (Hang- 
zhou, China). All experiments were performed 
in accordance to the guidelines for animal care 
and use of Zhejiang province and Zhejiang 
Academy of Medical Sciences, and approved 
by the Ethics Committee of Zhejiang Academy 
of Medical Sciences (No. SCXK (Zhe) 2008-
0033, and No. SYXK (Zhe) 2008-0113).
HFHCD for induction of NAFLD and cirrhosis
Gerbils were divided randomly into nine gr- 
oups: one control group (n = 8) and eight time 
point model groups (each group, n = 8). The 
control group animals were fed a normal diet 
for 24 weeks, while the model group animals 
were fed an HFHCD. Based on former reports 
[29], we developed a new diet recipe (China 
Patent No. CN 102106476 A) to establish the 
model, which is similar to the western diet and 
containing the following components: 10% egg 
yolk powder (Zhejiang Changxing Ags Biologi- 
cal Products Co., Ltd.), 7% lard oil (purchas- 
ed from local supermarket), 2.5% cholesterol 
(Huadong Pharmaceutical Co., Ltd) and 0.2% 
cholate (Huadong Pharmaceutical Co., Ltd). 
The nutritional differences of the diets are 
shown in Supplementary Table 1.
Experimental design
Every eight model animals were sacrificed at 
the end of week 3, 6, 9, 12, 15, 18, 21 and 24 
for dynamic pathological and mechanical stud-
ies. Eight control animals were spared at the 
end of week 24. Blood samples were collected 
from abdominal aorta [30], allowed to clot for 
2 hours at room temperature, centrifuged 
(3,500 × g, 10 min), and the supernatant was 
used for measurement of alanine transami-
nase (ALT), aspartate transaminase (AST), 
CHO, TG, HDL-C, low density lipoprotein choles-
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terol (LDL-C) and glucose (GLU). Liver sam- 
ples were obtained from the central part of 
the largest liver lobe. Liver homogenate was 
prepared to determine the content of FFA; and 
the following fibrosis indexes: type I collagen, 
type III collagen, transforming growth factor β1 
(TGF-β1), and platelet-derived growth factor 
(PDGF), which were examined by western blot-
ting (see Supplementary). Another part of the 
liver sample was fixed by 10% formalin and 
embedded in paraffin for histological study, 
and then were stained with hematoxylin and 
eosin (HE) and with Masson trichrome (for 
collagen). Besides, liver biopsy specimens we- 
re also immunohistochemically examined for 
Kupffer cells by assessing the expression of 
the receptor CD68, and HSC by evaluating the 
activation of the marker of HSC: alpha-smooth 
muscle actin (αSMA). As a double check, type I 
collagen and type III collagen were appraised 
as well as Kupffer cells and HSC by immunohis-
tochemical examination. Meanwhile, for lipid 
accumulation assessment, electron micro-
scope was employed to observe the liver 
tissue.
Biochemical analysis
The levels of serum ALT, AST, CHO, TG, GLU, 
LDL-C, and HDL-C were determined by an auto-
matic chemical analyzer (HITACHI 7100, Ja- 
pan). Commercial kits (Huifeng Science & Te- 
chnology Co. Ltd., Shanghai, China; Jiancheng 
Biotech. Sci. Inc., Nanjing, China) were used for 
these analysis. All the procedures were fol-
lowed as those stated in the protocols of the 
detection kits. Likewise, the levels of FFA in 
liver were examined by a Nonesterified free 
fatty acids assay kit (Jiancheng Biotech. Sci. 
Inc., Nanjing, China).
Histopathology, electron microscope observa-
tion and immunohistochemical analysis
For histopathological study, the liver sections 
were stained with HE and with Masson’s tri-
chrome. Histological steatosis, inflammation, 
and fibrosis were assessed semiquantitatively 
by a single-blinded pathologist, according to 
the scoring system proposed by Kleiner et al. 
[31]. During the assessment, a Leica micro-
scope (Leica DM2500, Germany) was used for 
the observation. In each liver section, images 
of 10 random fields were taken (10 × 2.5 origi-
nal magnification; 0.22 mm2 total area per 
image) for the judgment.
For transmission electron microscope obser- 
vation, one animal was selected randomly 
from each group. After the liver was washed 
by using 0.9% physiological saline, a piece of 
the hepatic tissue was cut off from the central 
part of the largest liver lobe (about 1 × 1 × 1 
mm). And then, the tissue was fixed in 2.5% 
glutaraldehyde for 4 hours at 4°C. Later, the 
samples were sent to electron microscopic 
laboratory (Virus Research Institute, Chinese 
Academy of Sciences), to gain the transmission 
electron microscope result.
The Kupffer cell, hepatic stellate cell, type I 
collagen, and type III collagen were detected 
using the common immunohistochemical me- 
thod (see Supplementary). In order to show the 
fibrosis progression during the HFHCD induc-
tion clearly, an improved German immuno- 
histochemical scoring (GIS) system [32] was 
employed to access the immunohistochemical 
slices. The percentage of positive cells was 
graded as follows: 0, negative; 1, up to 10% 
positive cells; 2, 11% to 20%; 3, 21% to 30%; 4, 
31% to 40%; 5, 41% to 50%; 6, 51% to 60%; 7, 
61% to 70%; 8, 71% to 80%; and 9, > 80%. The 
intensity of marker expression was graded as 
follows: 0, negative; 1, weakly positive; 2, mod-
erately positive; 3, strongly positive. The final 
immunoreactive score equals to the product of 
the percentage of positive cells multiply the 
highest staining intensity.
Statistical analysis
Data are presented as the mean ± SD and com-
pared by analysis of variance after validation 
of homoscedasticity using Bartlett’s chi-squa- 
re test. Statistical comparisons were carried 
out using the SPSS Statistics 19 system (IBM 
Corporation, Armonk, New York, USA) and free- 
ly available R programming language (v 3.2.5). 
The R package “scatterplot3d”, “lmtest”, “psy- 
ch”, “ggm”, “car”, “psy”, and “ggplot2” were 
used in this study. The data set distribution was 
closer to a normal distribution. Then, a two-
sample, two-sided t-test was applied to deter-
mine the significance of the differences be-
tween model group and the corresponding 
control group. The acceptable level of statisti-
cal significance was set at P < 0.05.
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Results
Histological and biochemical assessment of 
HFHCD induced NAFLD and cirrhosis
In the morphological observations, the control 
group gerbils have shown soft livers with nor-
mal color and smooth surfaces, whereas the 
model group gerbils presented different de- 
grees of pathological liver over time. The liver 
of model group animals became swollen and 
hard and turned pale yellow, the edge of the 
pathological liver developed into a blunt shape, 
and the liver surface changed into an irregular 
pattern with whitish micronodules and mac-
ronodules (Figure 1F), which indicated the liv- 
er damage changes over the HFHCD induction 
time.
The comparison of histopathological study of 
the model group and control group has also 
shown a similar tendency as morphology ob- 
servation. As exhibited in Figure 1A, no dis-
cernible histological alterations could be identi-
fied in control group. They had complete cyto-
plasm, sinusoidal spaces, distinct nucleus, 
nucleolus and central vein. In contrast, the mo- 
del group presented a full blown cirrhosis fea-
ture accompanied with steatosis (Figure 1E), 
and a significantly higher fibrosis score (Sup- 
plementary Table 2). These results provided 
microscopic evidence that indicated the sig- 
nificant liver damage changes over the HFH- 
CD induction time. The independent pathologi-
cal judgment [31] (Supplementary Table 2)
show the obvious steatosis stage (Figure 1B) 
between 3 to 6 weeks, the NASH stage (Figure 
1C, 1D) between 9 to 18 weeks, and liver fi- 
brosis stage (Figure 1D) after 12 weeks HFHCD 
induction. Finally, the cirrhosis model (Figure 
1E, 1F) can be seen to have been established 
after 21 weeks HFHCD induction (Figure 2).
Supplementary Tables 3 and 4 presented the 
results of raised ALT, AST, GLU, TG, CHO and 
body weight of model animals (0-9 weeks). 
These results exhibited the well repeated ger- 
bil NASH model as we have reported before 
[27, 28].
In accord with the pathological assessment 
and transaminases results, in comparison to 
the control group, the immunohistochemical 
analysis and western blot results also show a 
compelling increase of type I (P < 0.05, after 
21 weeks) and type III collagens (P < 0.01, after 
15 weeks) in the model group (Figure 3). As 
shown in Figure 3B, After 15 weeks of HFHCD 
Figure 1. Hepatic injury of gerbil during the HFHCD treatment. A. Representative HE stained section of control liver. 
B. Representative HE section of the simple steatosis stage (6 weeks HFHCD treatment, gerbil liver). C. Representa-
tive HE section of NASH without fibrosis (12 weeks HFHCD treatment, gerbil liver). D. Representative HE section of 
NASH with fibrosis (18 weeks HFHCD treatment, gerbil liver). E. Representative HE section of cirrhosis stage (24 
weeks HFHCD treatment, gerbil liver). F. Representative morphology picture of cirrhosis stage (24 weeks HFHCD 
treatment, gerbil liver).
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induction, collagen III was increasing consis-
tently (P < 0.001); on the other hand, collagen I 
was significantly increased again at week 24 (P 
< 0.01). Both of the type I and type III collagens 
reached the biochemical peak at week 24, 
which strengthen the assurance of the model.
Activation of Kupffer cell and HSC
Kupffer cells and hepatic stellate cells are gen-
erally regarded as keys of the fibrosis and cir-
rhosis mechanisms. In this study, Kupffer cells 
and hepatic stellate cells were evaluated by 
assessing the expression of the receptor CD- 
68, and αSMA, the marker of activated HSC. 
As expected, the control group animals only 
have few Kupffer cells, and no activated HSC 
has been observed (Figure 3). Whereas, the 
model groups show many Kupffer cells and 
HSC (Figure 3) after 12 weeks of HFHCD in- 
duction. Compare with the control group, the 
increase of Kupffer cells after 12 weeks HF- 
HCD induction is significant: 12 weeks, P < 
0.01; 15 weeks, P < 0.05; 18 weeks, P < 0.01; 
21 weeks, P < 0.001; and 24 weeks, P < 0.01. 
The comparison of the activated Kupffer cells 
between 18 weeks and 21 weeks model gr- 
oups also shows compelling difference (P < 
0.05). The HSC changes of model groups over 
the HFHCD induction time are significant too, 
as well as the tendency of Kupffer cells. HSC 
appeared together with the ballooning hepato-
cytes. Compared with the control group, the 
increase of HSC numbers after 12 weeks HF- 
HCD induction is notable: 12 weeks, P < 0.01; 
15 weeks, P < 0.01; 18 weeks, P < 0.001; 21 
correlation coefficient between the other vari-
ables and HSC measurements were calculated 
to be 0.68 for TGF-β1, 0.41 for PDGF and 0.62 
for Kupffer cell (Figure 4B). The strong positive 
correlation between those chronic inflamma-
tion factors and HSC implies that the HFHCD 
induced cirrhosis may be partly caused by the 
chronic inflammation factors [11, 33], which 
directly induced the activation of HSC. Besides 
that, partial correlation analysis shows that 
TGF-β1 has a strong positivecorrelation with 
HSC, its partial correlation coefficient is 0.65, 
which is similar to their correlation coefficient 
mentionedabove (0.68, TGF-β1 and HSC). This 
result suggests that TGF-β1 and HSC has a 
strong and direct positive correlation. The fol-
lowed-up statistical analysis also indicates 
TGF-β1 is prior to HSC and is the Granger-cau- 
se of HSC (P < 0.05, optimal lagorder is deter-
mined by Akaike information criteria) [34, 35]. 
Since TGF-β1 is the Granger-cause of HSC, 
along with HFHCD feeding time, we calculated 
their linear regression formula: HSC = 2.467 + 
1.279e-5 × TGF-β1 + 1.831e-1 × Time (R2 = 
0.764, TGF-β1 is based on the gray scale val-
ues of western blotting result [36]) (Figure 
4B), and their coefficients are significant (P < 
0.001). Its good linear relation offers TGF-β1 
as a new supplement indicator for fibrosis diag-
nosis and prediction.
Dynamic relationship between hepatic lipid 
metabolism and cirrhosis
The lipid accumulation in liver was observed 
by transmission electron microscopy. The ul- 
Figure 2. The four stages of the NAFLD-cirrhosis gerbil model and the tested 
indexes in this study.
weeks, P < 0.001; and 24 
weeks, P < 0.001.
Hepatic expression of fibro-
genesis mediators implicated 
in the fibrogenic process
Based on the western blot 
analysis, after 15 weeks HF- 
HCD induction, model group 
animals showed a significant 
protein expression increase of 
TGF-β1 and PDGF (Figure 3C), 
which are known to induce 
HSC activation and prolifera-
tion and also are responsible 
for the inflammation and vas-
cular flow disarrangement. The 
Nonalcoholic fatty liver disease cirrhosis model in gerbil
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trastructure of hepatic cells was normal in con-
trol group: the membrane was well defined; 
chromatin was uniformly distributed. No fat 
droplet could be found in mitochondria, endo-
cytoplasmic reticulum or liver cell. The cell 
nucleus was overall in shape (Figure 5A). In 
contrast, the model group animals have many 
fat droplets and formation of vacuoles in liver 
cells. After 3 weeks HFHCD induction, the small 
lipid droplets appeared everywhere in the cell 
(Figure 5B, 5C). And then, during the HFHCD 
induction process, the fat droplets accumulat-
ed into some big lipid droplets (Figure 5E, 5F). 
The observed lipid accumulation changes in- 
dicated the severity degree of hepatic lipid 
metabolism disorder, which also complies with 
the NAFLD progression. In addition, total CHO, 
LDL-C, FFA and HDL-C were increased dramati-
cally in relation to the HFHCD induction time 
(Figures 5D and 4A). To illustrate the dynamic 
relationship between hepatic lipid metabolism 
and cirrhosis, a focused principal components 
analysis (FPCA) has been performed [37]. Sin- 
ce TG and FFA have shown distinct rise and fall 
tendency, and the turning point is at 18 weeks 
and 12 weeks (fibrosis stage). Accordingly, 
FPCA also reflected the differences. The analy-
sis has shown significant positive correlation 
between HSC and all the tested factors (P < 
0.05), except FFA and TG (Figure 4B). FPCA 
revealed that HDL-C, LDL-C, and CHO belong to 
the main factors in this experiment, and their 
increment can promote the fibrosis progression 
(Figure 4B).
Figure 3. Hepatic fibrosis of gerbil during the HFHCD treatment. (A) Representative immunohistochemical sections 
(model groups: collagen III, 15 weeks HFHCD treatment; collagen I, 21 weeks HFHCD treatment; HSC, 21 weeks 
HFHCD treatment; Kupffer cell, 24 weeks HFHCD treatment) and (B) German immunohistochemical scoring (GIS) of 
collagen III, collagen I, αSMA, and CD68 of gerbil liver. (C) Western blot results of collagen III, collagen I, PDGF, and 
TGF-β1.*P < 0.05, **P < 0.01, ***P < 0.001.
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Discussion
Our novel data shows that in the first 9 weeks 
HFHCD induction, the model’s body weight, 
GLU, ALT, AST, CHO, and TG levels were signifi-
cantly increased (Supplementary Tables 3 
and 4). The histological scoring system also 
shows the NASH features. Therefore, the gerbil 
NASH model has been repeated well as our 
former studies [27, 28]. During the whole stu- 
dy period, a number of features in common 
with human disease were found: (i) the exces-
sive accumulation of FFA, (ii) blood lipid me- 
tabolism disorder, (iii) cellular ballooning, (iv) 
immunohistochemistry changes, and (v) liver 
morphology modifications [38-40]. Progres- 
sion of the cirrhosis from NAFLD was clearly 
subdivided into stages (Figure 2) allowing the 
study of the progression of the disease and 
the correlation with the HFHCD induction time. 
The result indicates a strong positive correla-
tion between lipids metabolism and cirrhosis, 
which mimics the clinical disease. Therefore, 
the gerbil NAFLD cirrhosis model has been 
established and can be used to study NAFLD 
progression, especially the cirrhosis stage, for 
a better understanding of the disease patho-
physiology and for medicine development.
Besides, during the longitudinal study we have 
observed a distinct rise and fall tendency of 
TG and FFA levels, and their turning points are 
Figure 4. The dynamic relationship between gerbil hepatic lipid metabolism and fibrogenesis indicators and media-
tors. A. The blood lipids changes of gerbil during the HFHCD treatment. B. The positive correlation of gerbil HSC, CI, 
CIII, Kupffer cell, PDGF, TGF-β1, CHO, HDL-C, LDL-C, FFA and TG (P < 0.05, except FFA and TG); and two linear regres-
sion models. The dynamic relationship between HDL-C and HSC. The dynamic relationship between TGF-β1 and HSC 
(TGF-β1 is based on the gray scale values of western blotting result [36]). *P < 0.05, **P < 0.01.
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in the fibrosis stage. The decreased TG level 
seems rare based on our knowledge. Coin- 
cidently, a Harvard group has also reported the 
similar tendency recently [41]. Their clinical 
study statistically analyzed 11947 cases, and 
pointed out that lower triglyceride levels may 
indicate more advanced liver disease. The fi- 
brosis progression caused liver dysfunction 
can possibly lead to resultant impairment in 
lipoprotein synthesis and result in decreased 
triglyceride export. The accompanied FFA level 
changes are the support of the inference.
Since the gerbil NAFLD cirrhosis model has 
been well developed, which not only possess 
the similar clinical features but also can be 
clearly divided into stages, we tried FPCA to 
find out the closest indexes of HSC for the 
dynamic monitoring and disease progression 
prognosis. The FPCA [37] result indicated that 
HDL-C, LDL-C, and CHO are closely related with 
HSC and other fibrosis indicators in the NA- 
FLD-cirrhosis progression. The similar increas-
ing tendency of Kupffer cells, HSC, TGF-β1, 
and PDGF also supports previous research into 
this area which indicated that the Kupffer cells 
can secrete TGF-β1, and PDGF to stimulate 
fibrosis development through the mitogenic 
stimuli of them on HSC [42]. Surprisingly, the 
growth of HDL-C was found abnormal during the 
HFHCD induction time, which has aroused our 
attention. In this study, HDL-C not only has 
strong positive correlation with HSC (r = 0.556, 
P < 0.05), but also has a good linear relation-
ship with HSC along with the HFHCD induction 
time (Figure 4B, HSC = 1.047 + 0.756 × HDL-C 
+ 0.178 × Time, R2 = 0.823, P < 0.001). A few 
NAFLD studies [43, 44] have also reported 
the same HDL-C increase tendency, which may 
suggest the special mechanism during the 
NAFLD-caused fibrosis progression. So we lo- 
oked into the CHO/HDL-C ratio to further in- 
spect the model. It is interesting to note that 
the CHO/HDL-C ratios show constant growth 
tendency during the HFHCD induction, and 
have good linear relationship with HSC (HSC = 
3.542 - 0.655 × CHO/HDL-C + 0.237 × Time, 
R2 = 0.802, P < 0.001). These results are 
dramatically consistent with the clinic reports 
[45, 46] and may imply the special status of 
HDL-C in the NAFLD progression. Considering 
the possible HFD or HFHCD differences, envi-
ronment differences, and animal differences 
in other labs, we suggest using CHO/HDL-C 
ratio as a convenient blood indicator for the 
standard gerbil model assessment. For this 
Figure 5. Hepatic lipid metabolism of gerbil during the HFHCD treatment. (light gray circular area is accumulated 
triglyceride and the dark gray circular area is cholesteryl ester). A. Representative transmission electron micrograph 
of control liver. B. Representative transmission electron micrograph of the fatty liver steatosis stage (3 weeks). C. 
Representative transmission electron micrograph of the NASH stage (9 weeks). E, F. Representative transmission 
electron micrograph of the fibrosis and cirrhosis stages (15 and 21 weeks). D. The FFA level changes in gerbil liver 
during the HFHCD treatment.**P < 0.01, ***P < 0.001.
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purpose, the blood sample can be collected 
from the tail vein or the cheek vein (300 μL 
blood is enough for detecting more than two 
indexes), and the regression equation might be 
used to determine the NAFLD stage and suit-
able experiment time.
As we presented in the result, the pros and 
cons of this gerbil NAFLD cirrhosis model can 
easily be listed. First of all, this gerbil model 
can induce NASH within 9 weeks, and can 
develop stable cirrhosis after 21 weeks HFH- 
CD induction (Supplementary Table 2). This is in 
contrast to, as Robert Schierwagen reported, 
most of the existing HFD induced NAFLD mod-
els that need a minimum of 15 weeks induc- 
tion and that hardly show stable fibrosis [23, 
47-49]. Secondly, the model has the same 
fibrosis progression (eg. HSC activation, colla-
gen III and collagen I deposition, bridging fibro-
sis, and cirrhosis) as in the clinic [38-40], and 
leads to a stable cirrhosis stage. It can thus be 
suggested that the gerbil model can cover the 
whole NAFLD disease spectrum to make up 
the NAFLD model deficiency [11, 12]. Having 
the same features and etiologies as the clini- 
cal process combined with its stable cirrhosis 
stage, is key advantage of this gerbil model 
for the NAFLD and cirrhosis investigations. As 
still remaining limitations of the gerbil model 
we can mention that the additional diet cho- 
lesterol may cause some metabolism differ-
ences. Further studies are required to address 
whether alterations in diet composition can 
lead to a refined model, which can completely 
reproduce the human disease mechanism. Be- 
sides that, the 21 weeks cirrhosis induction 
time is still not very convenient. If the research 
purpose is only to study the cirrhosis stage, it 
would be meaningful to further improve the 
HFHCD recipe for the gerbil model.
In summary, we have firstly established a ger- 
bil NAFLD cirrhosis model, which has stable 
fibrosis stage and can be used for NAFLD longi-
tudinal study. The study shows for the first time 
that the lipids metabolism disorder is accom- 
panied with liver damage during the whole 
NAFLD progression, and they have a positive 
correlation along with the HFHCD induction 
time. The dynamic observation also initially de- 
tected the noticeable rise and fall tendency of 
TG and FFA levels during the NAFLD progres-
sion. Moreover, the good linear relationship 
between CHO/HDL-C and HSC pioneered that 
the CHO/HDL-C ratio can be a convenient bio-
marker for the NAFLD progression judgment, 
especially for the fibrosis progression diagnosis 
and prediction.
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Supplementary materials & methods: western blot, immunohistochemical method
Western blot: type I collagen, type III collagen, TGF-β1, and PDGF
Hepatic cells were lysed in RIPA lysis buffer (Beyotime Biotechnology, Jiangsu, China) with 1 mM phenyl-
methylsulphonyl fluoride (PMSF) (Amresco, Solon, OH, USA). After the samples were centrifuged at 
10000 g for 5 minutes, protein levels in the supernatants were measured by a BCA assay kit (Beyotime 
Biotechnology, Jiangsu, China). For each sample, 50 μg of protein was separated on 10% polyacryl-
amide electrophoresis (160 V, 2 h), and transferred to a polyvinylidenedifluoride membrane (400 mA, 2 
h at 4°C). The membranes were preblocked (1 h at room temperature) with 5% skimmed milk in Tris-
buffered saline-Tween-20. Subsequently, membranes were incubated overnight at 4°C with the primary 
antibodies: anti-Collagen I, anti-Collagen III, anti-TGFβ1, and anti-PDGF (Abcam, Cambridge, MA, USA). 
After wash three times, the membranes were incubated with secondary antibodies HRP-labeled goat 
anti-rabbit IgG (H + L) (Beyotime Biotechnology, Jiangsu, China) (1:5000) for 1 hour and followed by 
another three washes for preparing the visualization. Finally, the results were visualized with enhanced 
chemiluminescence (ECL, Millipore, Billerica, MA), and were quantitative analyzed by using a 
BioshineChemiQ 4600 mini chemiluminescence imaging system (Bioshine, Shanghai, China).
Immunohistochemical method: Kupffer cell, hepatic stellate cell, type I collagen, and type III collagen
After the liver sections were dewaxed in xylene and graded alcohols, the sections were hydrated and 
washed in phosphate-buffered saline. Afterwards, the peroxidase in the sample was inhibited by 3% 
H2O2 for 10 minutes, and then the sections were pretreated in a pressure cooker in sodium citrate buf-
fer, followed by an incubation step with 5% bull serum albumin for 30 minutes to block the slides. The 
primary antibodies used were: anti-α-SMA (product code: ab5694, Abcam, Cambridge, MA, USA), anti-
CD68 (product code: ab53444, Abcam, Cambridge, MA, USA), anti-collagen I (product code: ab34710, 
Abcam, Cambridge, MA, USA), and anti-collagen III (product code: ab7778, Abcam, Cambridge, MA, 
USA). These primary antibodies were applied overnight in a refrigerator at 4°C. After washing, a second-
ary antibody, anti-rabbit mouse immunoglobulins (clone MR12/53, DakoDiagnostika, Hamburg, 
Germany) was added inside and incubated at 37°C for 30 minutes. Reaction products were visualized 
by incubation with diaminobenzidine (Liquid DAB+, DakoDiagnostika, Hamburg, Germany) and counter-
stained with hematoxylin. And then, a leica microscope (Leica DM2500, Germany) was used to measure 
the optical density values. We scanned 10 images for each slice (10 × 2.5 original magnification; 0.22 
mm2 total area per image).
Supplementary Table 1. Nutritional differences between 
standard diet and high-fat, high-cholesterol diet
Standard diet High-fat high-cholesterol diet
Total calorific value 16.55 MJ/kg 19.19 MJ/kg
Carbohydrates 44.70% 36.40%
Crude protein 22.10% 19.30%
Fat (cholesterol) Minor* 2.74%
Other fat 3.00% 13.26%
Crude fiber 3.30% 3.50%
Crude ash 7.80% 3.20%
Others (water, etc.) 19.10% 21.60%
*about 0.156 mg/g diet.
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Supplementary Table 2. NAFLD clinical research network scoring system definitions and scores
Item Definition 3
Time (week)
6 9 12 15 18 21 24
Steatosis Grade < 33% 8 0 1 0 0 0 0 0
33%-66% 0 8 7 6 3 0 0 0
> 66% 0 0 0 2 5 8 8 8
Microvesicular steatosis Not present 8 8 2 0 1 0 0 0
Present 0 0 6 8 7 8 8 8
Fibrosis Stage None 8 8 8 4 0 2 1 0
Perisinusoidal or periportal 0 0 0 4 0 0 0 0
Mild, zone 3, perisinusoidal 0 0 0 0 2 1 0 0
Moderate, zone 3, perisinusoidal 0 0 0 0 5 2 2 0
Portal/periportal 0 0 0 0 1 3 3 3
Bridging fibrosis 0 0 0 0 0 0 1 2
Cirrhosis 0 0 0 0 0 0 1 3
Inflammation Lobular inflammation No foci 8 5 7 4 1 0 1 0
< foci per 200 × field 0 3 1 4 7 8 7 8
> 2 foci per 200 × field 0 0 0 0 0 0 0 0
Portal inflammation None to minimal 8 8 3 4 2 3 5 4
Greater than minimal 0 0 5 4 6 5 3 4
Liver cell injury Ballooning None 8 3 0 0 0 0 0 0
Few balloon cells 0 5 1 0 0 0 0 0
Many cells/prominent ballooning 0 0 7 8 8 8 8 8








(n = 8, score means the number of animals with described symptom at each time point. NAFLD: nonalcoholic fatty liver disease; NASH: nonalco-
holicsteatohepatitis).
Supplementary Table 3.  Biochemical characteristics of control group and model groups during the 
first 9 weeks HFHCD induction
Control 3 weeks 6 weeks 9 weeks
ALT (U/L) 70.44 ± 4.03 73.80 ± 9.93 88.00 ± 15.80** 77.71 ± 21.26
AST (U/L) 164.38 ± 17.85 192.67 ± 35.42* 179.25 ± 29.26 193.86 ± 31.36*
GLU (mmol/L) 4.55 ± 0.40 6.28 ± 1.13** 6.56 ± 0.56** 7.48 ± 1.55**
TG (mmol/L) 1.11 ± 0.43 1.95 ± 0.40** 1.51 ± 0.43* 0.48 ± 0.14**
CHO (mmol/L) 2.66 ± 0.70 10.42 ± 2.47** 7.89 ± 2.89** 4.75 ± 0.87**
*P < 0.05, **P < 0.01.
Supplementary Table 4. Body weight of control group and 
model groups during the first 9 weeks HFHCD induction
Body weight (g) 3 weeks 6 weeks 9 weeks
Control 41.51 ± 3.71 47.89 ± 2.93 54.16 ± 5.02
Model 40.13 ± 6.20 58.93 ± 6.04** 64.64 ± 5.67**
**P < 0.01.
